Vital Signs - Biomarkers in Clinical Trials - A Significant Competitive Advantage?

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on October 9, 2006, provides a strategic overview and discussion of the use of biomarkers in clinical trials. Additionally, an emerging company profile is provided for Dendritic Nanotechnologies Inc., a company that specializes in the development and commercialization of dendrimers and dendritic polymers. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of September 25 - September 29, 2006.

Table of Contents

Vital Signs - Biomarkers in Clinical Trials - A Significant Competitive Advantage?Vital Signs: 9 October 2006This week's issue:




Related Research

Release Date : 08-Sep-17

Region : North America

Release Date : 22-Aug-17

Region : North America

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.